The possibility of preventing Alzheimer's disease before symptoms appear represents perhaps the most significant shift in neurodegenerative medicine since the field's inception. Current evidence suggests that targeting amyloid plaques in cognitively healthy individuals who test positive for Alzheimer's biomarkers could fundamentally alter disease trajectory rather than merely slowing decline.
Anti-amyloid antibodies like aducanumab and lecanemab have demonstrated modest but measurable cognitive benefits in people with mild cognitive impairment. Now, researchers are investigating whether these same therapeutic mechanisms can prevent cognitive decline entirely when deployed in preclinical stages. The approach targets individuals who show biological markers of Alzheimer's pathology—elevated amyloid deposits detected through PET scans or blood tests—but retain normal cognitive function. Early trials focus on safety profiles, optimal dosing strategies, and whether intervention timing fundamentally changes outcomes versus traditional treatment approaches.
This preventive paradigm could revolutionize Alzheimer's care, transforming it from reactive symptom management to proactive disease prevention. The implications extend beyond individual patients to healthcare economics and public health policy. However, significant hurdles remain: developing reliable blood-based biomarker tests for widespread screening, establishing cognitive assessment protocols sensitive enough to detect preservation rather than improvement, and ensuring equitable access to expensive treatments. The success of these prevention trials could accelerate regulatory pathways for related therapies, potentially creating a new category of neurodegenerative medicine focused on maintaining cognitive health rather than treating cognitive loss.